CDK4, cyclin dependent kinase 4, 1019

N. diseases: 433; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 AlteredExpression group BEFREE Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center derived B-cell lymphomas. 31849147 2020
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 PosttranslationalModification group BEFREE WGA and SBA reduced levels of B cell lymphoma-2 (Bcl-2), phosphorylation of Bcl-2-associated death promoter (Bad), cyclin-dependent kinase 4 (Cdk4), and phosphorylation of the retinoblastoma (Rb). 31231312 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 GeneticVariation group BEFREE In cells overexpressing S100A6, the expression levels of interleukin (IL)-8, cyclin-dependent kinase (CDK)5, CDK4, minichromosome maintenance complex component 7 (MCM7) and B-cell lymphoma 2 (Bcl2) were noticeably increased. 28123545 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 Biomarker group BEFREE Collectively, these findings establish a context-specific tumor suppressor function for CDK4 that prevents genomic instability, which contributes to B cell lymphoma. 24614102 2014
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 AlteredExpression group BEFREE To compare the expression status of G1 cyclins, these EBV-associated lymphoma lines (6 EBV[-] human SCID mouse lymphoma lines, 13 human B cell lymphomas and 8 samples of human tonsil tissue) were examined by reverse transcription-polymerase chain reaction-Southern blotting, Western blotting and immunohistochemistry. mRNA expression of cyclin D1 (CCND1), cyclin D2 (CCND2), cyclin E (CCNE), cyclin-dependent kinase 2 (CDK2) and 4 (CDK4) was found in all 3 types of lymphomas. 11291051 2001
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.060 GeneticVariation group BEFREE Twenty primary central nervous system lymphomas (PCNSL) from immunocompetent patients (nineteen B-cell lymphomas and one T-cell lymphoma) were investigated for genetic alterations and/or expression of the genes BCL2, CCND1, CDK4, CDKN1A, CDKN2A, MDM2, MYC, RB1, REL, and TP53. 9546285 1998